BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $26.28 billion. The enterprise value is $11.34 billion.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, before market open.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 246.24 million shares outstanding. The number of shares has decreased by -0.51% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 246.24M |
| Shares Change (YoY) | -0.51% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 17.91% |
| Owned by Institutions (%) | 22.46% |
| Float | 99.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.64 |
| Forward PS | 13.30 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.18, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.18 |
| Quick Ratio | 9.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -80.81 |
Financial Efficiency
Return on equity (ROE) is -3.94% and return on invested capital (ROIC) is -4.05%.
| Return on Equity (ROE) | -3.94% |
| Return on Assets (ROA) | -3.67% |
| Return on Invested Capital (ROIC) | -4.05% |
| Return on Capital Employed (ROCE) | -6.50% |
| Revenue Per Employee | $438,324 |
| Profits Per Employee | -$122,258 |
| Employee Count | 6,772 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.89 |
Taxes
| Income Tax | -27.35M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.33% in the last 52 weeks. The beta is 1.29, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +29.33% |
| 50-Day Moving Average | 102.67 |
| 200-Day Moving Average | 109.48 |
| Relative Strength Index (RSI) | 54.27 |
| Average Volume (20 Days) | 1,214,419 |
Short Selling Information
| Short Interest | 6.11M |
| Short Previous Month | 5.20M |
| Short % of Shares Out | 6.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.04 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $2.97 billion and -$827.93 million in losses. Loss per share was -$3.45.
| Revenue | 2.97B |
| Gross Profit | 2.36B |
| Operating Income | -1.38B |
| Pretax Income | -269.98M |
| Net Income | -827.93M |
| EBITDA | -1.10B |
| EBIT | -1.38B |
| Loss Per Share | -$3.45 |
Full Income StatementBalance Sheet
The company has $15.25 billion in cash and $316.69 million in debt, giving a net cash position of $14.93 billion or $60.65 per share.
| Cash & Cash Equivalents | 15.25B |
| Total Debt | 316.69M |
| Net Cash | 14.93B |
| Net Cash Per Share | $60.65 |
| Equity (Book Value) | 20.46B |
| Book Value Per Share | 85.10 |
| Working Capital | 15.23B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$276.37 million and capital expenditures -$299.29 million, giving a free cash flow of -$624.24 million.
| Operating Cash Flow | -276.37M |
| Capital Expenditures | -299.29M |
| Free Cash Flow | -624.24M |
| FCF Per Share | -$2.54 |
Full Cash Flow StatementMargins
Gross margin is 79.39%, with operating and profit margins of -46.49% and -27.89%.
| Gross Margin | 79.39% |
| Operating Margin | -46.49% |
| Pretax Margin | -28.81% |
| Profit Margin | -27.89% |
| EBITDA Margin | -37.14% |
| EBIT Margin | -46.49% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.51% |
| Shareholder Yield | 0.51% |
| Earnings Yield | -3.15% |
| FCF Yield | -2.38% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $141.55, which is 32.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $141.55 |
| Price Target Difference | 32.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 3.84% |
| EPS Growth Forecast (5Y) | -14.76% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 8.04 and a Piotroski F-Score of 3.
| Altman Z-Score | 8.04 |
| Piotroski F-Score | 3 |